Escherichia coli (ATCC 700336), STZ-Induced Diabetic UTI Model, CFU Data
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model assesses the efficacy of test articles for protection against a urinary tract infection with Escherichia coli. It may be used to assess efficacy of small molecules, vaccines and biologics.
SPECIES
Escherichia coli
STRAIN COMMON NAME
#700336
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
SOURCE
STRAIN SOURCE
American Type Culture Collection (ATCC)
STRAIN SOURCE ID
ATCC 700336
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 female specific-pathogen-free C3H-HeN mice aged 4-5 weeks are used. Type 1 diabetes is induced by intraperitoneal injection of 150 mg/kg streptozocin (STZ) 13 and 10 days prior infection. Animals are fasted overnight before STZ injection. Infection is established on day 0 in animals under pentobarbital anesthesia (50 mg/kg, intraperitoneal injection). A 50 µL suspension of Escherichia coli is inoculated transurethrally into the bladder using a urinary catheter. Vehicle and/or test substances are then administered (IV, PO, IP, or SC) 2 and 14 hours later or 24 and 36 hours later. At 26 hours or 48 hours after inoculation, animals are euthanized with CO₂ asphyxiation, the bladder and kidneys are aseptically removed, and the tissues are homogenized in PBS pH 7.4. Serial dilutions of tissue homogenates are plated onto Nutrient Agar medium for bacterial enumeration (CFU/tissue).
CRITERIA FOR SIGNIFICANCE
An agent is found to be bactericidal at a given concentration if treatment results in a 2-log reduction in counts over 26 hr relative to the baseline inoculum.
TURNAROUND TIME
STANDARD
40 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences